IN THE CLAIMS:

Please amend claims 1, 2, 4, 6, 8, 9, and 11, and cancel claims 12 and 14-22, without prejudice. Please add new claims 23-27.

This listing of claims will replace all prior versions, and listings, of claims in the application:

STATUS OF THE CLAIMS:

1. (Currently Amended) A method for identifying a compound capable of treating a hematological disorder, comprising:

a) combining a compound to be tested with a sample comprising a polypeptide selected from the group consisting of:

i) a polypeptide comprising the amino acid sequence of SEQ ID NO:64;

ii) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:63;

iii) a polypeptide at least 95% identical to the amino acid sequence of SEQ ID NO:64; and

iv) a polypeptide encoded by a nucleic acid molecule at least 95% identical to the nucleotide sequence of SEQ ID NO:63;

~~9118, 990, 17662, 81982, 630, 21472, 17692, 19290, 21620, 21689, 28899, 53659, 64549, 9465, 23544, 7366, 27417, 57259, 21844, 943, 2061, 5891, 9137, 13908, 14310, 17600, 25584, 27824, 28469, 38947, 53003, 965, 56639, 9661, 16052, 1521, 6662, 13913, 12405 or 5014 polypeptide~~ under conditions suitable for binding of the test compound to the polypeptide; ~~and~~

b) detecting binding of the test compound to the polypeptide to thereby identify a compound which binds to the polypeptide;

c) combining the compound selected in part b) with CD34 progenitor cells expressing the polypeptide; and

d) determining if the cells differentiate into mature cells of differentiated hematopoietic cell lineage,

thereby identifying a compound capable of treating a hematological disorder.

2. (Currently Amended) The method of claim 1, wherein the compound is selected from the group consisting of a small molecule, a peptide and~~or~~ an antibody.

3. (Previously Presented) The method of claim 1, wherein the polypeptide further comprises heterologous sequences.

4. (Currently Amended) The method of claim 1, wherein the sample~~polypeptide~~ is an isolated polypeptide, a membrane-bound form of an isolated polypeptide or a cell comprising the polypeptide.

5. (Previously Presented) The method of claim 4, wherein the cell is a hematological cell.

6. (Currently Amended) The method of claim 1, wherein the hematological disorder is selected from the group consisting of:~~a disorder associated with, but not limited to,~~ anemia, neutropenia and~~or~~ thrombocytopenia.

7. (Previously Presented) The method of claim 1, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

a) a competition binding assay;

b) an immunoassay; and

c) a yeast two-hybrid assay.

8. (Currently Amended) A method for identifying a compound capable of modulating hematopoiesis~~treating a hematological disorder~~, comprising:

a) combining a compound to be tested with a sample comprising a polypeptide selected from the group consisting of:

i) a polypeptide comprising the amino acid sequence of SEQ ID NO:64;

ii) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:63;

iii) a polypeptide at least 95% identical to the amino acid sequence of SEQ ID NO:64; and

iv) a polypeptide encoded by a nucleic acid molecule at least 95% identical to the nucleotide sequence of SEQ ID NO:63;

~~host cell expressing a 9118, 990, 17662, 81982, 630, 21472, 17692, 19290, 21620, 21689, 28899, 53659, 64549, 9465, 23544, 7366, 27417, 57259, 21844, 943, 2061, 5891, 9137, 13908, 14310, 17600, 25584, 27824, 28469, 38947, 53003, 965, 56639, 9661, 16052, 1521, 6662, 13913, 12405 or 5014 polypeptide~~ under conditions suitable for binding of the test compound to the polypeptide; ~~and~~

b) detecting binding of the test compound to the polypeptide to thereby identify a compound which binds to the polypeptide;

c) combining the compound selected in part b) with CD34 progenitor cells expressing the polypeptide; and

d) determining if the cells proliferate,

thereby identifying a compound capable of modulating hematopoiesis~~treating a hematological disorder~~.

9. (Currently Amended) The method of claim 8, wherein the compound is selected from the group consisting of a small molecule, a peptide, and an antibody~~or an antisense nucleic acid molecule~~.

10. (Previously Presented) The method of claim 8, wherein the polypeptide further comprises heterologous sequences.

11. (Currently Amended) The method of claim 8, wherein the sample is an isolated polypeptide, a membrane-bound form of an isolated polypeptide or a cell comprising the polypeptide~~host cell is a hematological cell~~.

12. (Canceled)

13. (Previously Presented) The method of claim 8, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

a) a competition binding assay;

b) an immunoassay; and

c) a yeast two-hybrid assay.

14-22. (Canceled)

23. (New) The method of claim 1, wherein the binding of the test compound to the polypeptide is detected by an assay for an activity of the polypeptide.

24. (New) The method of claim 23, wherein the assay for an activity is a phosphatase assay.

25. (New) The method of claim 8, wherein the binding of the test compound to the polypeptide is detected by an assay for an activity of the polypeptide.

26. (New) The method of claim 25, wherein the assay for an activity is a phosphatase assay.

27. (New) The method of claim 11, wherein the wherein the cell is a hematological cell.